Prazosin

Base Information

• Chemical Name: Prazosin
• CAS No.: 19216-56-9
• Molecular Formula: C19H21N5O4
• Molecular Weight: 383.407
• Hs Code.: 2934999090
• European Community (EC) Number: 242-885-8
• UNII: XM03YJ541D
• DSSTox Substance ID: DTXSID4049082
• Nikkaji Number: J10.000E
• Wikipedia: Prazosin
• Wikidata: Q425296
• NCI Thesaurus Code: C767
• RXCUI: 8629
• Pharos Ligand ID: BD967KAHXVAM,BDCXZQTBSBYV
• Metabolomics Workbench ID: 42807
• ChEMBL ID: CHEMBL2
• Mol file: 19216-56-9.mol

Synonyms:Furazosin;HCL, Prazosin;Hydrochloride, Prazosin;Minipress;Pratsiol;Prazosin;Prazosin HCL;Prazosin Hydrochloride

Chemical Property of Prazosin

Chemical Property:

• Vapor Pressure: 3.4E-16mmHg at 25°C
• Melting Point: 278-280°C
• Refractive Index: 1.651
• Boiling Point: 638.366 °C at 760 mmHg
• PKA: pKa 6.54(50% EtOH) (Uncertain)
• Flash Point: 339.871 °C
• PSA: 106.95000
• Density: 1.353 g/cm³
• LogP: 3.17070
• Storage Temp.: 2-8°C
• Solubility.: DMSO (Slightly), Methanol (Slightly, Heated)
• Water Solubility.: 3.2mg/L(22.5 oC)
• XLogP3: 2
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 4
• Exact Mass: 383.15935417
• Heavy Atom Count: 28
• Complexity: 544

Purity/Quality:

99%, ^*data from raw suppliers

Prazosin ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antihypertensive Agents
• Canonical SMILES: COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC
• Recent ClinicalTrials: Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests
• Recent EU Clinical Trials: Etude préliminaire de l’efficacité d’un α1 bloquant (la prazosine) en prévention de la survenue d’un état de stress post-traumatique chez des patients présentant un état de stress aigu.
• Uses: Antihypertensive. Prazosin is used for treating mid-to-moderate hypertension. When using this drug, blood pressure is reduced without any significant change in indicators of cardiac function such as frequency, coronary flow, or cardiac output. Prazosin is used to treat average or moderate hypertension. Upon taking this drug, blood pressure drops without substantial changes in indicators of heart work, such as rate, coronary flow, and cardiac output. Prazosin is used for weak to moderate hypertension.
• Therapeutic Function: Antihypertensive
• Clinical Use: Prazosin is effective in reducing all grades of hypertension. The drug can be administered alone in mild and (in some instances) moderate hypertension.When the hypertension is moderate or severe, prazosin generally is given in combination with a thiazide diuretic and a -blocker. The antihypertensive actions of prazosin are considerably potentiated by coadministration of thiazides or other types of antihypertensive drugs. Prazosin may be particularly useful when patients cannot tolerate other classes of antihypertensive drugs or when blood pressure is not well controlled by other drugs. Since prazosin does not significantly influence blood uric acid or glucose levels, it can be used in hypertensive patients whose condition is complicated by diabetes mellitus or gout. Prazosin and other -antagonists find use in the management of benign prostatic obstruction, especially in patients who are not candidates for surgery. Blockade of -adrenoceptors in the base of the bladder and in the prostate apparently reduces the symptoms of obstruction and the urinary urgency that occurs at night.
• Drug interactions: Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Antidepressants: enhanced hypotensive effect with MAOIs. Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect - avoid. Beta-blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect. Calcium-channel blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect. Diuretics: enhanced hypotensive effect, increased risk of first dose hypotensive effect. Moxisylyte: possibly severe postural hypotension when used in combination.

Technology Process of Prazosin

There total 13 articles about Prazosin which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 66.0%

→ prazosin (19216-56-9)

Guidance literature:

With potassium carbonate; In N,N-dimethyl-formamide;

Reference yield: 61.0%

2-furanoic acid (88-14-2) + 4-amino-6,7-dimethoxy-2-piperazin-1-ylquinazoline (60547-97-9) → prazosin (19216-56-9)

Guidance literature:

With N-ethyl-N,N-diisopropylamine; ethyl cyanoglyoxylate-2-oxime; In N,N-dimethyl-formamide; at 20 ℃;

DOI:10.1111/cbdd.12534

Reference yield:

2-furancarbonyl chloride (527-69-5) + 4-amino-6,7-dimethoxy-2-piperazin-1-ylquinazoline (60547-97-9) → prazosin (19216-56-9)

Guidance literature:

2-furancarbonyl chloride; 4-amino-6,7-dimethoxy-2-piperazin-1-ylquinazoline; With macroporous polymer-supported carbonate; In dichloromethane; at 20 ℃;

With PS-Trisamine; In dichloromethane;

DOI:10.1016/j.tetlet.2006.02.047

upstream raw materials:

2-furancarbonyl chloride

4-amino-6,7-dimethoxy-2-piperazin-1-ylquinazoline

4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester

2-chloro-6,7-dimethoxyquinazolin-4-amine

Refernces

• 1、 Petty, Aaron,Idippily, Nethrie,Bobba, Viharika,Geldenhuys, Werner J.,Zhong, Bo,Su, Bin,Wang, Bingcheng. "Design and synthesis of small molecule agonists of EphA2 receptor". . p. 1261 - 1276. Retrieved 2017/11/27.
• 2、 -. "THERAPY FOR COMPLICATIONS OF DIABETES". . . Retrieved 2009/07/02.